Archive for the ‘clinical study retractions’ Category
The article was titled “NIDCAP in preterm infants and the neurodevelopmental effect in the first 2 years,” and its first author was Laura Fazilleau of University Hospital Côte de Nacre.
Age has retracted a 2012 article by a group of scientists from the National Institutes of Health and Brigham and Women’s Hospital in Boston after an NIH inquiry turned up evidence of data manipulation in the work.
The article, “Aging decreases rate of docosahexaenoic acid synthesis-secretion from circulating unesterified α-linolenic acid by rat liver,” came from the lab of Stanley Rapoport, chief of the brain physiology and metabolism section of the National Institute on Aging.
In 2011, a group of researchers at Columbia University reported in Cell that they had been able to convert skin cells from patients with Alzheimer’s disease into functioning neurons — a finding that raised the exciting prospect of “made to order” brain cells for patients with the degenerative disease. As one researcher not involved with the study, led by Asa Abeliovich, put it:
“[This is] simply a remarkable and complete piece of work which will now set a standard for stem cell work in neurological disease. The standard of the characterization of the neuronal cultures is very high,” John Hardy at University College London, U.K., wrote to [Alzforum]. He was not involved in the work but is taking a similar approach in his own lab.
According to the abstract of “Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons:”
On Tuesday, we broke the news of the retraction in Circulation of a paper on cardiac stem cells by a group of researchers being investigated by Harvard Medical School and the Brigham and Women’s Hospital. Today, The Lancet has issued an Expression of Concern about another paper led by Piero Anversa, the last author of the Circulation paper.
Circulation has retracted a 2012 study by a group of Harvard heart specialists over concerns of corrupt data, and the university is investigating. The group was led by Piero Anversa, a leading cardiologist, and Joseph Loscalzo — who will be familiar to readers of Circulation as the editor in chief of that journal. (Anversa’s also on the editorial board).
Back in January 2013, we wrote about the retraction of a paper in Diabetes that the authors had “submitted without knowledge of inherent errors or abnormalities that they recognized in retrospect after submission.”
Now, Molecular Pain has retracted a paper by the same authors, this time for data manipulation. The article, “Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states,” was written by Cory Toth, a clinical neuroscientist at the University of Calgary, in Canada, and colleagues. It has been cited eight times, according to Thomson Scientific’s Web of Knowledge.
Toth said of the Diabetes article at the time:
Read the rest of this entry »
The International Journal of Cardiovascular Imaging has retracted a 2013 paper by a group of researchers from Italy. The reason: plagiarism.
The paper was titled “Diagnostic accuracy of 320-row computed tomography as compared with invasive coronary angiography in unselected, consecutive patients with suspected coronary artery disease,” and it came from scientists in Rome led by Francesco Pelliccia of the Department of Heart and Great Vessels at Sapienza University.
no primary data can be located, and no evidence has been found that the study described in the article was conducted.
Follow this timeline, if you would:
- August 14, 2013: Former UConn researcher Dipak Das, who was found to have committed misconduct, submits a paper to Oxidative Medicine and Cellular Longevity.
- September 19, 2013: Das dies.
- October 17, 2013: Das submits revisions to his paper in Oxidative Medicine and Cellular Longevity.
- October 18, 2013: Paper accepted.
- January 12, 2014: Paper published.
That would appear to be what the timeline on the paper — which lists Das as corresponding author, along with a Gmail address — says:
Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of one researcher to note his Novartis affiliation. The company has apologized.
Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”